Companies › Mercator MedSystems
1 active drug program in 8 registered trials: 4 Phase 1, 2 Phase 3, 2 Phase 2; Cardiovascular, Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Temsirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Peripheral Artery Disease; Alveolar Rhabdomyosarcoma; Advanced Rare Tumours; Endometrial Adenocarcinoma … | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02567435 | Temsirolimus | Phase 3 | Alveolar Rhabdomyosarcoma | Oncology | Jun 2023 |
| NCT01087554 | Temsirolimus | Phase 1 | Advanced Cancer | Oncology | Aug 2026 |
| NCT01396408 | Temsirolimus | Phase 2 | Advanced Rare Tumours | Oncology | Dec 2026 |
| NCT00977574 | Temsirolimus | Phase 2 | Endometrial Adenocarcinoma | Oncology | Mar 2027 |
| NCT01375829 | Temsirolimus | Phase 1 | Adult Solid Neoplasm | Oncology | Mar 2027 |
| NCT02389309 | Temsirolimus | Phase 1 | Advanced Malignant Solid Neoplasm | Oncology | Oct 2027 |
| NCT04433572 | Temsirolimus | Phase 3 | Peripheral Artery Disease | Cardiovascular | Feb 2028 |
| NCT01187199 | Temsirolimus | Phase 1 | Advanced Cancer | Oncology | Apr 2028 |
Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis Rapamycin Holdings AgelessRx Novaliq Palvella Therapeutics Jiangsu Simcere Pharmaceutical Aadi Bioscience
Rapamycin Holdings Aadi Bioscience Ablative Solutions Novaliq Guerbet
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.